SuperworthIDEXX Laboratories, Inc. IDXX
Medical - Diagnostics & Research, Healthcare
$506.67
−1.70%
- Market cap
- $39.9B
- PE
- 35.6×
- 10y median 54.8×
- Forward PE
- Price to sales
- 8.8×
- EV/EBIT
- 27.4×
- Revenue, 12 months
- $4.6B
- +13% on a year ago
- Net margin
- 25.0%
- Free cash flow yield
- 3.1%
IDEXX Laboratories trades at 35.6× trailing earnings, cheaper than 100% of the last ten years. Revenue was $4.6B over the last twelve months, up 13% on a year earlier with a 25% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $901.6M | $964.1M | $1B | $975.5M | $954.3M+6% | $998.4M+4% | $1.1B+11% | $1.1B+13% | $1.1B+14% | $1.1B+14% | $1.2B+10% | |
| Cost of revenue | $375.4M | $371M | $384.4M | $379.5M | $383.6M+2% | $375M+1% | $414.7M+8% | $421.9M+11% | $432.5M+13% | $418.1M+12% | $437.5M+6% |
| Gross profit | $526.2M | $593.1M | $619.2M | $596M | $570.7M+9% | $623.4M+5% | $694.7M+12% | $683.4M+15% | $658.1M+15% | $722.7M+16% | $779.1M+12% |
| R&D | $51.8M | $52.6M | $55.5M | $54M | $57.7M+11% | $59.1M+12% | $61.9M+12% | $63.4M+18% | $66.8M+16% | $65.8M+11% | $65.4M+6% |
| SG&A | $229.1M | $241.5M | $299.9M | $238.2M | $251.2M+10% | $247.8M+3% | $259.8M−13% | $265.1M+11% | $275.7M+10% | $294.4M+19% | $288.1M+11% |
| $245.3M | $299M | $263.8M | $303.9M | $261.7M+7% | $316.5M+6% | $373M+41% | $354.8M+17% | $315.6M+21% | $362.6M+15% | $425.6M+14% | |
| Interest expense | $9.3M | $7.9M | $8.1M | $7.7M | $7.5M−19% | $7.7M−3% | $11.3M+40% | $10.7M+38% | $10.5M+40% | $7.7M+1% | $10.2M−10% |
| Pre-tax income | $239.7M | $295.5M | $259.1M | $298.9M | $256.4M+7% | $310.1M+5% | $362.4M+40% | $344.8M+15% | $307M+20% | $355.4M+15% | $417.2M+15% |
| $45.1M | $59.9M | $55.8M | $66.1M | $40.2M−11% | $67.4M+13% | $68.4M+23% | $70.2M+6% | $58.8M+46% | $77M+14% | $78.8M+15% | |
| Net income | $194.5M | $235.6M | $203.3M | $232.8M | $216.1M+11% | $242.7M+3% | $294M+45% | $274.6M+18% | $248.2M+15% | $278.4M+15% | $338.4M+15% |
| $2.32 | $2.81 | $2.44 | $2.80 | $2.62+13% | $2.96+5% | $3.63+49% | $3.40+21% | $3.08+18% | $3.47+17% | $4.27+18% | |
| 83.9M | 84M | 83.4M | 83.1M | 82.5M−2% | 81.9M−2% | 81M−3% | 80.7M−3% | 80.7M−2% | 80.2M−2% | 79.3M−2% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times IDEXX Laboratories's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $42.5B | 34.5× | 32.8× | 6.1× | +7% | 15.0% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .